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To reveal the biological and pathological roles of anti-GM1 antibody in Guillain–Barré syndrome (GBS), we examined its effects on nerve
growth factor (NGF) induced TrkA autophosphorylation (NGF-TrkA signaling) in PC12 cells, a sympathetic nerve cell line. The NGF-TrkA
signaling is enhanced by exogenous GM1 ganglioside and this phenomenon is regarded as one of the functional aspects of GM1. The IgGs
purified from patients' sera inhibited the NGF-TrkA signaling in GM1 pre-incubated PC12 cells. The degrees of inhibition by IgGs from patients
paralleled their immunological reactivity to GM1. In addition, the IgGs also inhibited the neurite outgrowth of NGF-treated PC12 cells.
Immunoglobulins in the rabbit sera, which were immunized by GM1, also caused a similar suppressive phenomenon. These results suggested that
the anti-GM1 antibody could play roles in pathophysiology in anti-GM1 antibody positive GBS through interfering with the neurotrophic action
of NGF and GM1 mediated signal modulation including NGF-TrkA signaling. It is suggested that the modulation of GM1 function is one
important action of antibodies and could be one of the important mechanisms in GBS.
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In Guillain–Barré syndrome (GBS) and its variants there are
miscellaneous antibodies against certain gangliosides. The kind
of the antibody is closely related to the disease type and removal
of these antibodies by plasmapheresis is an effective treatment
to improve the diseases. Therefore these antibodies have been
postulated as effecter molecules in these peripheral neuropa-
thies. Particularly IgG class anti monosialogangliosides GM1
(GM1) antibodies have been implicated as potential pathogenic
agents [1–3]. However the roles of these antibodies in the
pathophysiology of GBS and molecular mechanisms to impair
the nerve tissues are still unclear.
Recently GM1 has been known as not only a structural
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doi:10.1016/j.bbadis.2007.01.011transduction [4]. For example exogenous GM1 enhances the
autophosphorylation of TrkA, a specific nerve growth factor
(NGF) receptor, induced by NGF (NGF-TrkA signaling) and
augments the neurite outgrowth in PC12 cells, a sympathetic
nerve cell line [5–7]. However, little attention has been paid to the
functional aspects of GM1 in the studies of GBS pathogenesis.
In this study, we adopted the potentiating effect of GM1 to
NGF-TrkA signaling on PC12 cells [5–7] as the assay system
for testing the biological activity of anti-GM1 antibodies, and
tried to reveal the mechanisms of GBS pathogenesis caused by
the anti-GM1 antibody.
2. Materials and methods
2.1. Isolation of immunoglobulin
Sera obtained from four GBS patients in the acute phase before
plasmapheresis (Table 1) and four age-matched normal volunteers were tested
for reactivity to GM1 [4] and Campylobacter jejuni by ELISA [8]. The IgG
immunoglobulins were isolated from these sera using Protein-L (Nab™ Protein-
Table 1
Clinical features of GBS patients
No. Age Sex Diarrhea Cranial
nerve
Severitya Recoveryb Electrophysiological
diagnosis
#1 52 F + − 4 4 AMAN
#2 24 M + − 4 2.5 AMAN
#3 45 M + − 3 2 AMAN
#4 26 M + − 5 36< AMAN
a Hughes functional grade [9] at the peak.
b Months until able to walk independently (Grade 2) from onset, AMAN:
Acute motor axonal neuropathy.
Table 2
Relative reactivities of sera from patients and controls against the GM1
GM1 ganglioside
IgG IgM IgA
Patients
#1 + + +
#2 + ++ +
#3 ++ + −
#4 +++ − −
Controls
#1 − − −
#2 − − −
#3 − − −
#4 − − −
(−), (+), (++) and (+++) mean <×160, ×160, ×320, ×640 respectively against the
indicated antigens using ELISA. Cut-off value is an average of healthy control
[8].
Fig. 1. Effects of GM1 incorporation to the NGF-TrkA signaling. (A) TrkA
phosphorylation was assessed by immunoblot analysis using anti-phospho-
tyrosine antibody. Arrowheads indicate TrkA. (B) Total TrkA levels were
determined using anti-Total TrkA antibody. (C) The ratio of phosphorylated
TrkA to total TrkA were normalized to net intensity values for GM1 untreated
controls and represented the mean with S.E. (error bar) of three replicate
experiments. The asterisk shows significant (P<0.05) difference between
indicated data pair.
544 T. Tanaka et al. / Biochimica et Biophysica Acta 1772 (2007) 543–548L Spin Chromatography kit, Pierce) and the samples were adjusted to 1 mg/ml
concentration and stored at −20 °C. In some experiments, IgG immunoglobulins
were used, from which anti-GM1 antibodies were depleted with the GM1
immobilized plate.
2.2. Cell cultures
PC12 cells (Human Science Research Resource Bank, Osaka) were
maintained in RPMI medium (RPMI1640, GIBCO BRL) supplemented with
10% heat-inactivated horse serum and 5% fetal bovine serum. To detect
phosphorylated proteins, cells were cultured on a collagen-coated 12-well
plate for 1 day, and then cultured in serum-free RPMI medium, when
indicated, with 50 μM GM1 (Sigma) for 12 h at 37 °C. After exposure to
GM1, cells were washed by serum-free RPMI medium and preincubated with
immunoglobulin isolated from patients' or control serum, or rabbit anti-GM1
IgG (Calbiochem) at the indicated concentration (25–100 μg/ml) for 30 min at
37 °C. Then cells were treated with NGF (7S NGF, Sigma) at 50 ng/ml for
30 min [5]. For morphological studies, the cells were cultured on 6-well plates
at 5×104 cells/well and treated with GM1, immunoglobulins and NGF in the
same conditions described above. After an additional 72 h of culturing, ten
different microscope fields were selected blindly, photographs taken, and the
neurite outgrowth was quantitated by comparing the neurite length and the
somal diameter. The neurite index was calculated as the ratio of the number of
cells with neurites (longer than 2× somal diameter) to those without neurites
[4].
2.3. Immunoprecipitation and immunoblotting
After NGF treatment, the cells were immediately washed by ice-cold PBS
with 1 mM Na3VO4 and lysed in lyses buffer (20 mM Tris–HCl, pH 8.0/
137 mM NaCl/1% NP-40/10% glycerol/50 mM NaF/1 mM Na3VO4/1 mM
PMSF/1 μg/ml leupeptine/10 μg/ml aprotinin) for 30 min on ice with agitation.
High-speed centrifuge (10,000×g) was performed to obtain cell free lysate and
the lysates were normalized for proteins. To detect TrkA phosphorylation, the
cell-free lysates were immunoprecipitated with anti-TrkA antibody agarose
conjugated (Santa-Cruz) at 4 °C over night. The resultant immunoprecipitates
were electrophoretically transferred to PVDF membranes after SDS-PAGE with
8% gels and were probed with anti-phosphotyrosine antibody (PY20, Zymed
Laboratories Inc). Detection was performed according to the manufacturer's
direction (ECL plus, Amersham). The membrane was reprobed with anti-TrkA
monoclonal antibody (Santa-Cruz) using manufacturer-specified reprobing
protocols (ECL manual, Amersham) [5–7]. To quantify the signals on the
films, densitometry was performed on personal computer using NIH Image and
the ratio of the phosphorylated proteins (p-TrkA) to the total amount of the
proteins (total TrkA) was calculated.
3. Results
3.1. Clinical and Immunological profiles of the patients
All four patients had diarrhea before the onset of GBS
symptoms and three patients showed positive anti-Campylo-bacter jejuni antibodies. They showed grade 3 to 5 severity
(Hughes functional grade [9]) and were electrophysiologically
diagnosed as acute motor axonal neuropathy (AMAN) on the
grounds that they showed fibrillation voltage in electromyo-
graphy and a decrease of compound muscle action potential
with normal conduction velocity. All patients had IgG type anti-
GM1 antibodies (Tables 1, 2).
3.2. Effects of GM1 incorporation on TrkA phosphorylation
It is reported that exogenous GM1 enhances TrkA
autophosphorylation caused by NGF [5–7]. To confirm this
phenomenon in our experimental system, we examined the
Fig. 3. Effects of IgG isolated from normal controls to the NGF-TrkA signaling
on GM1 incorporated PC12 cells. (A) TrkA phosphorylation was assessed by
immunoblot analysis using anti- phospho-tyrosine antibody. Arrowheads
indicate TrkA. (B) Total TrkA levels were determined using anti-Total TrkA
antibody. (C) The ratio of phosphorylated TrkA to total TrkAwere normalized to
net intensity values for NGF treated without the antibody controls and
represented the mean with S.E. (error bar) of three replicate experiments. There
were no significant differences between each data pairs.
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phosphorylation in PC12 cells. We observed about a 2-fold
increase in NGF-induced TrkA autophosphorylation in GM1-
treated PC12 cells compared with that in GM1-untreated cells
(Fig. 1).
3.3. Influence of GM1-immunized rabbitsT sera and
immunoglobulins derived from normal controls and patients
with GBS on NGF-TrkA signaling
To ascertain that anti-GM1 antibody inhibits the potentiating
effects of GM1 on NGF-TrkA signaling we performed
examinations using sera from GM1-immunized rabbits. It
suppressed the exogenous GM1 enhanced NGF-TrkA signaling
on GM1-treated PC12 cells with dose dependency (Fig. 2A–C)
and GM1 non-immunized rabbit's sera didn't show such
depressive effects (Fig. 2D).
Immunoglobulins from the four normal controls that did
not react to GM1 (Table. 2) showed no effects on the
TrkA autophosphorylation (Fig. 3). Immunoglobulins de-
rived from GBS patients inhibited the TrkA autophospho-
rylation dose-dependently (25 to 100 μg/ml) (Fig. 4) and
proportionally to their reactivity to GM1 (Table 2 and Fig.
5A–C). The anti-GM1 antibody-depleted immunoglobulinsFig. 2. Effects of antibody from GM1-immunized rabbit to the NGF-TrkA
signaling on GM1-incorporated PC12 cells. (A) TrkA phosphorylation was
assessed by immunoblot analysis using anti-phospho-tyrosine antibody.
Arrowheads indicate TrkA. (B) Total TrkA levels were determined using
anti-Total TrkA antibody. (C) The ratio of phosphorylated TrkA to total
TrkA were normalized to net intensity values for NGF treated without the
antibody controls and represented the mean with S.E. (error bar) of three
replicate experiments. The asterisks show significant (P<0.05) differences
between indicated data pairs. (D) The ratio of phosphorylated TrkA to total
TrkA. Cells were treated by 50 ng/ml NGF without rabbit's serum (1), with
serum from GM1 immunized rabbit (2) and with serum from unimmunized
rabbit (3).could no longer depress the TrkA autophosphorylation
(Fig. 5D).
3.4. Effects of immunoglobulins on NGF induced neurite
outgrowth
Photomicrographs of GM1-incorporated PC12 cells treated
with or without NGF and immunoglobulins are shown in
Fig. 6. There is no neurite formation in the absence of NGF
(Fig. 6A–D). NGF-induced neurite outgrowth is arrested by
the addition of immunoglobulins only from GBS patients (Fig.
6E–H). The neurite index indicates the almost completeFig. 4. Dose dependency of the IgG isolated from GBS patients to the NGF-
TrkA signaling on GM1-incorporated PC12 cells. Cells were stimulated by
50 ng/ml NGF. (A) TrkA phosphorylation was assessed by immunoblot analysis
using anti- phospho-tyrosine antibody. Arrowheads indicate TrkA. (B) Total
TrkA levels were determined using anti-Total TrkA antibody. (C) The ratio of
phosphorylated TrkA to total TrkA were normalized to net intensity values for
the antibody untreated controls and represented the mean with S.E. (error bar) of
three replicate experiments. The asterisks show significant (P<0.05) differences
between indicated data pairs.
Fig. 5. Effects of IgG isolated from GBS patients and a control to the NGF-TrkA
signaling on GM1 incorporated PC12 cells. Cells were stimulated by 50 ng/ml
NGF. (A) TrkA phosphorylation was assessed by immunoblot analysis using
anti- phospho-tyrosine antibody. Arrowheads indicate TrkA. (B) Total TrkA
levels were determined using anti-Total TrkA antibody. (C) The ratio of
phosphorylated TrkA to total TrkA were normalized to net intensity values for
the antibodies untreated controls and represented the mean with S.E. (error bar)
of three replicate experiments. There are significant (P<0.05) differences
between all data pairs without indicated by N.S. (D) The ratio of phosphorylated
TrkA to total TrkA. The black/white bars indicate the ratios obtained from GBS
patient's immunoglobulin before/after treatment by GM1 absorption column. 1:
Control #1, 2: Patient #4, 3: Patient #3, 4: Patient #1.
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immunoglobulins (Fig. 6E–H).
4. Discussion
In this paper we showed that the GBS (AMAN) patients' IgG,
which was reactive to GM1, inhibited the potentiating effect of
GM1 to NGF-TrkA signaling dose-dependently and interferedFig. 6. Morphological examinations of neurite outgrowth of GM1-incorporated PC12
E: IgG (−), B and F: 100 μg/ml IgG (control), C and G: 100 μg/ml IgG (patient #2), D
and methods).with the NGF induced neurite outgrowth in PC12 cells. It is
reasonable to suppose that this inhibition was due to the IgG
reacting directly to GM1, because sera from rabbits immunized
by GM1 had similar suppressing effects with dose-dependency
(Fig. 2), the degree of the inhibition was in proportion to the
reactivity to GM1 of incubated IgG (Fig. 4), and the anti-GM1
antibody-absorbed immunoglobulins didn't have such depres-
sive effects. On the other hand, O'Hanlon et al. reported that
monoclonal anti-GM1 IgM antibody from human neuropathy
induced small neuritogenic effects on PC12 cells [10]. Although
it appears to conflict with our results, this difference may arise
from the difference between IgG and IgM, in that anti-GM1 IgM
antibody relates to multifocal motor neuropathy rather than to
AMAN. These results suggested that the interaction between
GM1 on plasma membranes and anti-GM1 antibodies affected
the in vivo nervous system in the patients with anti-GM1–
antibody-positive GBS, particularly with AMAN in which
mainly affected on the axon of neuron, since the PC12 cell is not
a model of Schwann cell but nerve cell.
Ten to 42% of patients with GBS have high titer of anti-
GM1 antibody [11–13] and it has been suggested that IgG
antibodies against GM1 were strongly associated both with
axonal degeneration and reversible conduction failure in GBS
[14,15]. The effects of anti-GM1 antibodies on the electrical
activity of nerve tissues have been reported and it was
suggested that the antibodies could cause damages to neural
membranes or interfere with nerve conduction, or both [16–
19]. Nevertheless it is still difficult to explain, for example,
why there are many autoantibody-negative patients, or why
damage to the nerve conduction is reversible. These facts
suggest that we have to consider another functional aspect of
anti-GM1 antibody in GBS pathogenesis. Our results indicated
the functional significance of anti-GM1 antibody, which is the
interference with the biological function of GM1.
In some peripheral neuropathies neurotrophic factors and
their receptors' expression increased at peripheral nerve tissue
[20,21]. Nerve growth factors have various effects on neuronalcells at 72 h after NGF stimulation. A–D. NGF (−), E–H. 50 ng/ml NGF, A and
and H 100 μg/ml IgG (patient #4). The neurite index was shown (see Materials
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pathophysiological roles in GBS were unclear, the fact of
increased expression suggests their functional significance in
GBS pathophysiology. For example, it is well known that NGF
plays important roles in nerve regeneration and repair. In
addition, anti-GM1 antibodies and its subclass pattern were
tightly related to the slow recovery of GBS [22]. Owing to these
facts, our results suggested the association between the blocking
of neurotrophic factor signaling by anti-GM1 antibodies and the
prolonged recovery of GBS.
GM1 has been implicated in neuronal development and
differentiation [23]. Exogenous gangliosides promote neurite
outgrowth in primary cultures of neuron and cell lines, and
facilitate the repair of damaged neuronal cells. It was suggested
that the exogenous ganglioside exert these effects by modula-
tion of the function of growth factor receptors [6,7,24–26].
Therefore gangliosides could be understood as signaling
modulators for some types of receptors [27]. Mutoh et al.
have shown that the exogenously added GM1 gets tightly
associated with TrkA receptor protein and enhances the
autophosphorylation of the receptor [5]. It is still unclear how
GM1 enhances the NGF-TrkA signaling but it is suggested that
GM1 must be membrane bound to be effective, that is
incorporated into the cell membrane [27,28]. Recently GM1
has been known as one of the structural and functional
molecules in the micro domain of the cell membrane, the so-
called “functional lipid raft” especially in immune cells [29,30].
PC12 cells also have this micro domain which contain TrkA
[31]. Using confocal microscopy, we observed that anti-GM1
antibodies caused the aggregation of GM1 on the cell
membrane of PC12 cells (preliminary unpublished observa-
tion). It can be speculated that anti-GM1 antibodies interfere
with the NGF-TrkA signaling by functional modification of the
micro domain. If this speculation is true, anti-GM1 antibody
could affect other signal transduction not only in neural cells but
also in immune cells, for example brain derived nerve growth
factor (BDNF) signaling in motor neurons and T cell receptor
signaling in lymphocytes. These modulations could contribute
to the immunological pathophysiology in GBS.
In conclusion, the anti-GM1 antibody may have effects on
the pathophysiology in anti-GM1–antibody-positive GBS
through disturbing neurotrophic action. It is important to regard
the antibody as a modifier to GM1 function and, from this point
of view, further investigation is needed to elucidate the role of
the “GM1–anti-GM1 interaction” for understanding the GBS
pathogenesis.
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